Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
28.48
-0.23 (-0.80%)
At close: Feb 12, 2026
Market Cap10.41B +12.8%
Revenue (ttm)225.16M +1,560.5%
Net Income-583.52M
EPS-1.59
Shares Out366.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,861,223
Average Volume3,313,496
Open28.89
Previous Close28.71
Day's Range28.16 - 28.89
52-Week Range22.79 - 37.88
Beta0.77
RSI46.82
Earnings DateApr 30, 2026

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 793
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2024, SHA:688443's revenue was 30.09 million, an increase of 2384.11% compared to the previous year's 1.21 million. Losses were -797.27 million, -0.50% less than in 2023.

Financial Statements